Novo Nordisk: Over 1.3 million prescriptions for oral weight loss medication in Q1
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
```htmlAccording to Golden Ten Data on May 6, Novo Nordisk's financial report for the first quarter of 2026 shows that the oral weight-loss version of semaglutide Wegovy® tablets had more than 1.3 million prescriptions in a single quarter, with a cumulative total of over 2 million prescriptions, contributing 2.256 billion Danish kroner in sales. The report reveals that in March, the National Medical Products Administration officially approved the listing application for Ico Insulin Semaglutide injection (brand name: Rybelsus®) in China, which is the world's first and currently only approved weekly basal insulin/GLP-1RA combination preparation. It is reported that this innovative drug is planned to have its global launch in China in the second half of 2026.```
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$81,682.57
+1.12%
Ethereum
ETH
$2,381.88
+0.30%
Tether USDt
USDT
$0.9998
+0.01%
XRP
XRP
$1.44
+2.06%
BNB
BNB
$642.99
+2.30%
USDC
USDC
$0.9998
+0.00%
Solana
SOL
$88.31
+4.24%
TRON
TRX
$0.3425
+0.63%
Dogecoin
DOGE
$0.1164
+4.55%
Hyperliquid
HYPE
$44.33
+3.12%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now